Title
The potential clinical application of protein kinase C beta II peptide inhibitor or Gö 6983 in vascular endothelial dysfunction
Document Type
Article
Publication Date
2010
Abstract
Vascular endothelial dysfunction which is associated with increased oxidative stress and decreased endothelial-derived nitric oxide has been considered as a major initial event in various diseases, such as atherosclerosis, diabetes and ischemia/reperfusion (I/R) injury. Previously we found that a broad-spectrum protein kinase C (PKC) inhibitor (i.e., Gö 6983) and a specific PKC beta II peptide inhibitor (PKC βII-) were cardioprotective in myocardial I/R injury. However, the direct effects of Gö 6983 or PKC βII- on vascular endothelial dysfunction and the related leukocyte-endothelial interactions are still unclear. The leukocyte rolling, adherence and transmigration were estimated by using intravital microscopy in rat mesenteric postcapillary venules. We found that superfusion of NG -nitro-L-arginine-methyl-ester (L-NAME, 50 µM) induced endothelial dysfunction and significantly increased leukocyte-endothelial interactions within a 2 hour period compared to Krebs’ buffer control group (P
Recommended Citation
Chen, Qian; Rueter, Brian; Krass, Samuel; Zambrano, Christopher; Thomas, Shawn; Prince,, Catherine; Bell, Brandon; Chai, Vincent; Emrich, Jeffery; and Young, Lindon, "The potential clinical application of protein kinase C beta II peptide inhibitor or Gö 6983 in vascular endothelial dysfunction" (2010). PCOM Scholarly Papers. Paper 1.
http://digitalcommons.pcom.edu/scholarly_papers/1
Comments
This article has been peer reviewed. The published version is published in Current Topics in Pharmacology Volume 14, Pages: 11 - 24. It is available at http://www.researchtrends.net/tia/abstract.asp?in=0&vn=14&tid=11&aid=3050&pub=2010